Skip to main contentAI and Advanced
/
ABBOTINDIA · NSEBSE SENSEX74,781.76-0.16%BSE |
NIFTY 5023,398.1-0.34%NSE |
NIFTY BANK56,606.55+0.24%NSE |
NIFTY IT28,921.5+0.11%NSE |
NIFTY AUTO27,304.5-0.86%NSE |
NIFTY FMCG45,053.75-0.29%NSE |
NIFTY PHARMA26,532.4-0.09%NSE |
NIFTY 50022,866.5-0.37%NSE |
AB
NSE · Equity shares · Biotechnology & Drugs290.00 · 1.15%
Abbott India ABBOTINDIA
NSE:INR 25,550
BSE:INR 25,570
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for ABBOTINDIA
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 25,260
Day rangeINR 25,135 — INR 25,635
52-week rangeINR 25,049.28 — INR 34,063.99
Volume9,614
Market cap59,216.35
P/E35.32
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)6,929.05
Net Income (INR Cr)1,552.02
Rev Growth (5 Year %)9.96
EPS Growth (5 Year %)17.58
P/E Ratio35.32
Book Value2,244.97
EPS735.34
Price/BV11.38Computed
Research path: Interpret Abbott India's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ABBOTINDIAAbbott India1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 6,501.93 | 5,917.31 | 5,193.49 |
| Accumulated Depreciation Total | -177.92 | -163.74 | -146.25 |
| Cash Equivalents | 369 | 480.4 | 177.99 |
| Other Liabilities Total | 117.51 | 119.22 | 115.12 |
| Accrued Expenses | 128.53 | 51.06 | 47.76 |
| Common Stock Total | 21.25 | 21.25 | 21.25 |
| Other Equity Total | -9.46 | -8.61 | -3.19 |
| Other Current Assets Total | 26.97 | 44.67 | 17.64 |
| Prepaid Expenses | 9.27 | 8.79 | 9.01 |
| Total Assets | 6,501.93 | 5,917.31 | 5,193.49 |
| Current Portof LT Debt/Capital Leases | 38.33 | 38.92 | 46.47 |
| Cash | 73.33 | 80.19 | 113.75 |
| Total Equity | 4,774.19 | 4,233.15 | 3,698.89 |
| Long Term Investments | 2,178 | 719.7 | 1,618.42 |
| Retained Earnings(Accumulated Deficit) | 4,735.88 | 4,191.63 | 3,640.67 |
| Total Common Shares Outstanding | 2.12 | 2.12 | 2.12 |
| Property/Plant/Equipment Total-Gross | 510.97 | 511.34 | 374.64 |
| Tangible Book Valueper Share Common Eq | 2,244.97 | 1,989.1 | 1,737.58 |
| Total Liabilities | 1,727.74 | 1,684.16 | 1,494.6 |
| Total Debt | 171.99 | 196.67 | 83.23 |
| Short Term Investments | 1,790 | 2,554.31 | 1,827.97 |
| Cashand Short Term Investments | 2,232.33 | 3,114.9 | 2,119.71 |
| Total Receivables Net | 554.86 | 714.71 | 479.9 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Accounts Receivable-Trade Net | 385.21 | 612.55 | 346.15 |
| Property/Plant/Equipment Total-Net | 333.05 | 347.6 | 228.39 |
| Total Current Liabilities | 1,476.57 | 1,407.19 | 1,342.72 |
| Total Inventory | 947.26 | 882.04 | 619.58 |
| ESOP Debt Guarantee | 26.52 | 28.88 | 40.16 |
| Accounts Payable | 1,106.93 | 1,057.86 | 1,002.69 |
| Other Currentliabilities Total | 202.78 | 259.35 | 245.8 |
| Total Long Term Debt | 133.66 | 157.75 | 36.76 |
| Intangibles Net | 3.78 | 6.46 | 6.66 |
| Other Long Term Assets Total | 43.52 | 14.96 | 15.85 |
| Note Receivable-Long Term | 172.89 | 63.48 | 78.33 |
| Total Current Assets | 3,770.69 | 4,765.11 | 3,245.84 |
| Capital Lease Obligations | 133.66 | 157.75 | 36.76 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio2.14
Price to Sale Ratio8.55
Growth
Debt 5Yr CAGR %2.42
Margins
Operating Margin 12m26.21
Operating Margin 5y Avg23.76
Net Profit Margin 12m22.4
Net Profit Margin 5y20.08
Yield
Dividend Yield %1.89
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskModerate risk
Board Risk21.33
Analyst consensus
ConsensusStrong Buy
Consensus score1.57
Analyst opinions7
Strong Sell count0
Sell count0
Hold count1
Buy count2
Strong Buy count4
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 74.99%
- FII
- 0.38%
- MF
- 7.44%
- Other
- 17.19%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Abbott India Ltd. is Rated Sell by MarketsMOJO - Markets MojoMarket news · 4 Jun 2026, 10:31 am
Abbott India Ltd. is Rated Sell by MarketsMOJO Markets Mojo
Abbott India Ltd. Faces Bearish Momentum Amid Technical Downgrade - Markets MojoMarket news · 3 Jun 2026, 8:05 am
Abbott India Ltd. Faces Bearish Momentum Amid Technical Downgrade Markets Mojo
Abbott India Q4 FY26: Margin Resilience Masks Profit Volatility Amid Premium Valuation - Markets MojoMarket news · 1 Jun 2026, 1:05 am
Abbott India Q4 FY26: Margin Resilience Masks Profit Volatility Amid Premium Valuation Markets Mojo
Abbott India Ltd stock (INE358A01014): Q3 FY26 margin pressure keeps investors cautious - AD HOC NEWSMarket news · 28 May 2026, 8:34 pm
Abbott India Ltd stock (INE358A01014): Q3 FY26 margin pressure keeps investors cautious AD HOC NEWS
Abbott India Limited Appoints Swati Pathak as Associate Director - Operations, Effective June 1, 202626 - marketscreener.comMarket news · 25 May 2026, 12:30 pm
Abbott India Limited Appoints Swati Pathak as Associate Director - Operations, Effective June 1, 202626 marketscreener.com
Abbott India appoints Swati Pathak as Associate Director - Operations - scanx.tradeMarket news · 25 May 2026, 12:30 pm
Abbott India appoints Swati Pathak as Associate Director - Operations scanx.trade
Corporate actions
Events
- annual General MeetingAGM
- annual General MeetingAGM
- board MeetingsQuarterly Results
- dividendRs.525.0000 per share(5250%)Final Dividend
- dividendRs.131.0000 per share(1310%)Special Dividend
- annual General MeetingPOM
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
ShareKeyX Community
Discussion and sentiment for Abbott India
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Abbott India Limited is an India-based pharmaceutical company. The Company is involved in product development, manufacturing, sales, and customer service. It distributes products and solutions in multiple therapeutic categories, such as women's health, gastroenterology, cardiology, metabolic disorders and primary care. It operates in a single reportable business segment, which is Pharmaceuticals. The Company’s products include Arachitol Nano, Digeraft, Influvac, Colospa, Duphalac, Librax, Creon, Duphaston, Prothiaden, Cremaffin, Duvadilan, Thyronorm, Cremaffin Plus, Ganaton, Udiliv, Digene, Heptral, Vertin, Zolfresh, Citrosoda UTI, Digene Insta On The Go, Digeraft tablet, Duphaston OD, Pneumoshield 14, Prothiaden Neu, Vonefi, Levesam, and LOBATE M Skin Cream, among others. The Company sells its products through independent distributors primarily within India.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ABBOTINDIA
- BSE Code
- 500488
Questions
Stock FAQ
What is the symbol and ISIN of Abbott India?
Abbott India has the symbol ABBOTINDIA and ISIN - INE358A01014.
What is the current price of Abbott India?
Abbott India is currently trading at INR 25,550.00.
What are the year high and year low of Abbott India?
Abbott India has a year high of INR 34,063.99 and a year low of INR 25,049.28.
What is the market capitalization of Abbott India?
Abbott India has a market capitalization of INR 59,216.35 crore.
What is the P/E ratio of Abbott India?
Abbott India has a P/E ratio of 35.32.
What is the dividend yield of Abbott India?
Abbott India has a dividend yield of 1.89%.
How is the financial performance of Abbott India based on revenue, net income, and EPS?
Abbott India has revenue of INR 6,929.05 crore, net income of INR 1,552.02 crore, and EPS of INR 736.64.
What is the book value of Abbott India?
Abbott India has a book value of INR 2,244.97.
What is the debt-to-equity ratio of Abbott India?
Abbott India has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Abbott India?
Abbott India has a price-to-book ratio of 11.38 and a price-to-sales ratio of 8.55.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.